4-Thiouridine 5′-triphosphate

4-Thiouridine 5′-triphosphate (4-Thio-UTP) (treated at 30°C for 60 minutes) inhibits influenza A/X-31 vRNP-mediated UTP incorporation in a polymerase assay with an IC₅₀ of 45 μM ^[1].

4-Thiouridine 5′-triphosphate (0-25 µM; 1 minute) is a potent antagonist of ADP-induced aggregation in human PRP with an IC₅₀ of 7.5 µM, and also strongly antagonizes collagen-induced aggregation^[2].
4-Thiouridine 5′-triphosphate (5-fold IC₅₀, 7.5 µM) competitively displaces [³H]-ADP binding to the P2Y₁₂ receptor on washed human platelets^[2].
4-Thiouridine 5′-triphosphate (5 minutes) eliminates the inhibitory effect of ADP on PGE₁-stimulated cAMP in washed human platelets^[2].
4-Thiouridine 5′-triphosphate (25 µM; 5 minutes) reverses the ADP-induced decrease in PGE₁-mediated VASP Ser157 phosphorylation in human PRP^[2].
4-Thiouridine 5′-triphosphate (6-10 min) does not inhibit ADP-induced morphological changes in human platelets, which is consistent with the absence of P2Y₁ antagonism^[2].
4-Thiouridine 5′-triphosphate (compound IX) (1-100 µM) is a potent but non-selective agonist of human P2Y₂/P2Y₄/P2Y₆ receptors expressed in 1321N1 astrocytoma cells, with EC₅₀ values of 26 nM and 23 nM at P2Y₂ and P2Y₄, respectively^[3].